Back

QIAGEN completes U.S. QIAstat-Dx portfolio with FDA-cleared bacteria panel

Verifying
  • QIAGEN completed its U.S. QIAstat-Dx bloodstream infection portfolio.
  • The FDA cleared a new bacteria detection panel for the portfolio.
  • The clearance concerns QIAGEN’s U.S. QIAstat-Dx offering.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
QIAGEN completes U.S. QIAstat-Dx portfolio with FDA-cleared bacteria panel - CoinPost Terminal